UNCY: Unicycive Therapeutics Inc

UNCY新闻

• 12:35 Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
• 15:40 HC Wainwright & Co. 维持对 Unicycive Therapeutics 的“买入”评级，将目标价下调至 13 美元
• 15:40 HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13
• 11:07 Unicycive Therapeutics Resubmits Its FDA New Drug Application For Oxylanthanum Carbonate For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Expects PDUFA Date Six Months From Resubmission Date
• 11:07 Unicycive Therapeutics 重新提交了其用于治疗接受透析的慢性肾病患者高磷血症的氧化镧碳酸盐 FDA 新药申请；预计 PDUFA 日期为重新提交日期后六个月
• 20:37 Unicycive Says Suit Alleges Securities Law Violations Over Statements On Oxylanthanum Carbonate FDA Application
• 20:37 Unicycive表示，诉讼指控其关于氧化镧碳酸盐FDA申请的声明违反证券法
• 20:37 Unicycive Therapeutics Discloses Securities Class Action Filed September 3 Against Company And Certain Officers
• 20:37 Unicycive Therapeutics 披露公司及部分高管于 9 月 3 日遭提起证券集体诉讼
• 14:01 Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY)
• 13:05 Unicycive Therapeutics: Second CRL Exposes Execution Risk Behind OLC Story (NASDAQ:UNCY)